Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2018 | Future antibody avenues for cutaneous lymphoma treatment

Pietro Quaglino • 27 Sep 2018
EORTC CLTF 2018
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases T-Cell Lymphoma Antibodies Brentuximab vedotin Checkpoint inhibitors Mogamulizumab

Speaking from the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, Pietro Quaglino, MD, of the University of Turin, Turin, Italy, gives his insight into the novel therapies being explored for cutaneous T-cell lymphomas, including bretuximab vedotin and mogamulizumab .

More from Pietro Quaglino

2:25
Clinical scoring system for Sézary syndrome: results from a retrospective study
Pietro Quaglino • 1 Oct 2018
1:29
Current treatment landscape & unmet needs in cutaneous T-cell lymphoma: quality of life
Pietro Quaglino • 28 Sep 2018

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals